Apotex Celebrates Historic Health Canada Approval for LOQTORZI®, Groundbreaking Treatment for Nasopharyngeal Cancer Apotex Inc. proudly announces Health Canada has approved LOQTORZI®, the first immuno-therapy for recurrent nasopharyngeal cancer. This pivotal milestone brings new hope to patients.

Apotex Celebrates Historic Health Canada Approval for LOQTORZI®, Groundbreaking Treatment for Nasopharyngeal Cancer #Canada #Toronto #Cancer_Treatment #Apotex #LOQTORZI

STORM Therapeutics Begins Patient Dosing in Collaboration Using STC-15 with LOQTORZI and Welcomes New CMO STORM Therapeutics has initiated patient dosing in a study combining STC-15 with LOQTORZI. Atif Abbas, M.D., has been appointed CMO to drive this effort.

STORM Therapeutics Begins Patient Dosing in Collaboration Using STC-15 with LOQTORZI and Welcomes New CMO #Cambridge #United_Kingdom #STORM_Therapeutics #STC-15 #LOQTORZI

Toripalimab (Loqtorzi): Uses in Cancer, Side Effects, Dosage, Expectations, and More - OncoDaily Discover how Toripalimab (Loqtorzi) treats cancer, its side effects, dosage info, and what patients can expect from this innovative immunotherapy.

Toripalimab (Loqtorzi): Uses in Cancer, Side Effects, Dosage, Expectations, and More

oncodaily.com/drugs/toripa...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Toripalimab #Loqtorzi #FDA